Abstract
Lung cancer is a heterogeneous disease with several histologic subtypes. The two major pathologies, which account for approximately 70% of lung cancers, are adenocarcinoma (AD) and squamous cell carcinoma (SQ). Traditionally, these two subtypes have been categorized as non-small-cell lung cancer and treated similarly. However, they are different not only pathologically, but also functionally. For example, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), which assesses glucose metabolism in tumor tissues, shows that SQ has higher glucose metabolism than does AD.
Matrix metalloproteinases (MMPs) and their inhibitors play pleiotropic roles in cancer development, carcinogenesis, apoptosis, angiogenesis, invasion and metastasis. Expression of MMPs and their associated molecules is different among the subtypes of lung cancer. Expression levels of MMP-2, MMP-7, reversion-inducing cysteine-rich protein with Kazal motifs (RECK), tissue inhibitors of metalloproteinase (TIMP)-1, and TIMP-2 are higher in AD than in SQ. In contrast, expression levels of MMP-1, MMP-8, MMP-9 and TIMP-3 are higher in SQ than in AD.
Serum levels of a disintegrin and metalloproteinase (ADAM)-8 and ADAM-28 are higher in lung cancer patients than in healthy controls. High expression of ADAM-28 correlates with metastasis and recurrence, but there is no significant difference in ADAM-8 or ADAM-28 expression between AD and SQ.
It is necessary to recognize the differential expression patterns of MMPs, their endogenous inhibitors and associated molecules for each subtype of lung cancer in order to develop clinical markers, therapeutic inhibitors and treatment strategies using MMP inhibitors.
Keywords: ADAM, ADAMTS, Adenocarcinoma, Lung cancer, Metalloproteinase, MMP, RECK, Squamous cell carcinoma, TIMP, matrix metalloproteinases, disintegrin, thrombospondin, endogenous inhibitors, F-fluorodeoxyglucose positron emission tomography, cysteine-rich protein.
Anti-Cancer Agents in Medicinal Chemistry
Title:Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
Volume: 12 Issue: 7
Author(s): Yasuhiro Hida and Jun-ichi Hamada
Affiliation:
Keywords: ADAM, ADAMTS, Adenocarcinoma, Lung cancer, Metalloproteinase, MMP, RECK, Squamous cell carcinoma, TIMP, matrix metalloproteinases, disintegrin, thrombospondin, endogenous inhibitors, F-fluorodeoxyglucose positron emission tomography, cysteine-rich protein.
Abstract: Lung cancer is a heterogeneous disease with several histologic subtypes. The two major pathologies, which account for approximately 70% of lung cancers, are adenocarcinoma (AD) and squamous cell carcinoma (SQ). Traditionally, these two subtypes have been categorized as non-small-cell lung cancer and treated similarly. However, they are different not only pathologically, but also functionally. For example, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), which assesses glucose metabolism in tumor tissues, shows that SQ has higher glucose metabolism than does AD.
Matrix metalloproteinases (MMPs) and their inhibitors play pleiotropic roles in cancer development, carcinogenesis, apoptosis, angiogenesis, invasion and metastasis. Expression of MMPs and their associated molecules is different among the subtypes of lung cancer. Expression levels of MMP-2, MMP-7, reversion-inducing cysteine-rich protein with Kazal motifs (RECK), tissue inhibitors of metalloproteinase (TIMP)-1, and TIMP-2 are higher in AD than in SQ. In contrast, expression levels of MMP-1, MMP-8, MMP-9 and TIMP-3 are higher in SQ than in AD.
Serum levels of a disintegrin and metalloproteinase (ADAM)-8 and ADAM-28 are higher in lung cancer patients than in healthy controls. High expression of ADAM-28 correlates with metastasis and recurrence, but there is no significant difference in ADAM-8 or ADAM-28 expression between AD and SQ.
It is necessary to recognize the differential expression patterns of MMPs, their endogenous inhibitors and associated molecules for each subtype of lung cancer in order to develop clinical markers, therapeutic inhibitors and treatment strategies using MMP inhibitors.
Export Options
About this article
Cite this article as:
Hida Yasuhiro and Hamada Jun-ichi, Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650156
DOI https://dx.doi.org/10.2174/187152012802650156 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Sensoring Strategies Using Quantum Dots: A Critical View
Current Organic Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Apoptotic Effects of Bilirubin on Skin Cancer Cell Lines SK-MEL-3 (Melanoma) and A431 (Non-Melanoma)
Anti-Cancer Agents in Medicinal Chemistry Peptides Homing to Tumor Vasculature: Imaging and Therapeutics for Cancer
Recent Patents on Anti-Cancer Drug Discovery Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiating Between Primary Tumor, Metastatic Node and Normal Tissue in Head and Neck Cancer
Current Medical Imaging Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets A Squamous Cell Gallbladder Carcinoma: A Case Report and Literature Review
New Emirates Medical Journal